IRIS
DEFERRARI, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.533
Totale 19.533
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 19.533
Totale 19.533
Salva come PNG Salva come JPEG
Città #
Genova 14.508
Rapallo 2.153
Genoa 1.523
Vado Ligure 1.298
Bordighera 51
Totale 19.533
Salva come PNG Salva come JPEG
Nome #
L'AMMONIOGENESI RENALE NELL'UOMO 276
Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. 152
Chronic kidney disease in hypertension under specialist care: the I-DEMAND study 151
Androgen-mediated apoptosis of kidney tubule cells: role of c-Jun amino terminal kinase 147
Interorgan exchange of aminothiols in humans 146
Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy 143
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. 141
Oxidative stress mediates apoptotic changes induced by hyperglycemia in human tubular kidney cells 141
Ambulatory arterial stiffness index and renal abnormalities in primary hypertension 141
Inter-organ leptin exchange in humans 137
Vitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessions 136
Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. 135
C-reactive protein and target organ damage in untreated patients with primary hypertension. 132
ABNORMALITIES IN AMINO ACID METABOLISM IN CHRONIC RENAL FAILURE 132
Subclinical functional and structural renal abnormalities predict new onset type 2 diabetes in patients with primary hypertension 131
Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. 131
Correlation between pentosidine and endothelin-1 in subjects undergoing chronic hemodialysis. 130
Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. 129
Mild hyperuricemia and subclinical renal damage in untreated primary hypertension 129
PROTEIN TURNOVER IN THE HUMAN KIDNEY 126
Kidney protein dynamics and ammoniagenesis in humans with chronic metabolic acidosis 126
Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients 126
Creatinine clearance and early signs of target organ damage in primary hypertension 126
Free and sulfoconjugated catecholamines in normotensive uremic patients: effects of hemodialysis. 125
Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II 124
Predicting cardiovascular risk using creatinine clearance and an artificial neural network in primary hypertension 123
Mild renal dysfunction and renal vascular resistance in primary hypertension 122
5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. 122
Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. 122
Mechanisms of renal ammonia production and protein turnover 122
Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. 121
Arterial hypertension and microalbuminuria in IDDM: the Italian Microalbuminuria Study 121
METABOLIC SYNDROME AND CARDIOVASCULAR RISK IN PRIMARY HYPERTENSION. 121
Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS 121
AMINO ACID METABOLISM AND THE LIVER IN RENAL FAILURE 120
Coronary flow reserve is impaired in hypertensive patients with subclinical renal damage 120
Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension. 120
Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients 120
Midwall fractional shortening identifies extracardiac organ damage in essential hypertension 119
Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension 119
Phenylalanine hydroxylation across the kidney in humans 118
Renal ammoniagenesis in an early stage of metabolic acidosis in man 116
Renal and cardiac abnormalities in primary hypertension 116
INDIVIDUAZIONE DEL RUOLO DELLA GLUTAMINASI FOSFATO-DIPENDENTE E DELLA GLUTAMINASI FOSFATO-INDIPENDENTE NELLA PRODUZIONE RENALE DI AMMONIACA 115
Effects of a protein meal on blood amino acid profile in patients with chronic renal failure. 115
Splanchnic exchange of amino acids after amino acid ingestion in patients with chronic renal insufficiency 114
Blood pressure variability and multiple organ damage in primary hypertension 114
LEG METABOLISM OF AMINO ACIDS AND AMMONIA IN PATIENTS WITH CHRONIC RENAL FAILURE 114
Renal metabolism of C peptide in type I (insulin-dependent) diabetic patients 113
Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells 113
Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension 112
Amino acid imbalance in patients with chronic renal failure. 112
EFFECTS OF CHRONIC RENAL INSUFFICIENCY AND METABOLIC ACIDOSIS ON GLUTAMINE METABOLISM IN MAN 111
Microalbuminuria and subclinical cerebrovascular damage in essential hypertension 110
RENAL METABOLISM OF C-PEPTIDE IN MAN 110
Mild renal dysfunction and cardiovascular risk in hypertensive patients. 109
Treatment of diabetic nephropathy in its early stages 108
SPLANCHNIC AMINO ACID AND PROTEIN TURNOVER IN HUMANS: INSIGHT FROM ISOTOPE DILUTION AND CATHETERIZATION STUDIES 107
Disposal of exogenous amino acids by muscle in patients with chronic renal failure 107
Serum uric acid as a marker of target organ damage in primary hypertension 107
LEUCINE METABOLISM AND PROTEIN DYNAMICS IN THE HUMAN KIDNEY 107
Vascular permeability, blood pressure, and organ damage in primary hypertension 107
Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. 106
Skeletal muscle protein synthesis and degradation in patients with chronic renal failure 106
Renal ammoniagenesis in humans with chronic potassium depletion 106
Renal metabolism of amino acids in early insulin-dependent diabetes mellitus 106
Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure 105
Muscle protein synthesis and degradation in hemodialysis (HD) patients with protein-energy malnutrition (PEM) 105
Amino acid metabolism, substrate availability and the control of protein dynamics in the human kidney 104
Abnormal amino acid metabolism after amino acid ingestion in chronic renal failure 104
Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension 104
Global risk stratification in primary hypertension: the role of the kidney 103
RENAL AMMONIAGENESIS IN THE POST-PRANDIAL PERIOD 103
TT virus infection in haemodialysis patients 103
Sub-clinical organ damage in hypertension and obesity 103
Apoptosis induced by serum withdrawal in human mesangial cells. Role of IGFBP-3 102
Target organ damage and metabolic syndrome in non diabetic hypertensive patients 102
WHOLE BODY AND ORGAN PROTEIN TURNOVER IN CHRONIC RENAL FAILURE 101
BRAIN METABOLISM OF AMINO ACIDS AND AMMONIA IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY 101
Cardiovascular and renal risk assessment as a guide for treatment in primary hypertension. 101
Renal ammoniagenesis during the adaptation to metabolic acidosis in man. 101
Abnormalities in amino acid metabolism in patients with chronic renal failure. A pathophysiological approach to the nutritional treatment. I. Studies in the postabsorptive state 101
Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised? 101
Coronary flow reserve is impaired in uncomplicated hypertensive patients with renal dysfunction 100
Fibroblast Na+ - Li+ countertransport rate is elevated in essential hypertension 100
136) CKD awareness and blood pressare control in the primari care hypertensive population 100
DETERMINANTS OF THE PARTITION OF RENAL AMMONIA PRODUCTION BETWEEN URINE AND VENOUS BLOOD IN MAN WITH METABOLIC ACID-BASE DISTURBANCES 100
MICROALBUMINURIA, CARDIOVASCULAR, AND RENAL RISK IN PRIMARY HYPERTENSION. 99
Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC Study 99
Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria. 99
Serum uric acid levels predict new onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. 99
Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care. 99
Metabolic syndrome and microalbuminuria predict renal outcome in non-diabetic patients with primary hypertension: the MAGIC study. 99
Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. 99
Apoptosis in the kidneys of patients with type 2 diabetic nephropathy. 98
Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. 97
SUCCESSFUL TREATMENT OF MITOMYCIN C-ASSOCIATED HEMOLYTIC UREMIC SYNDROME BY PLASMAPHERESIS 97
Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes. 97
Role of blood cells in leucine kinetics across the human kidney 97
EFFECTS OF HEMODIALYSIS ON GUANIDINO-PROPIONIC ACID METABOLISM 96
Totale 11.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.281
article - articoli 47.962
book - libri 0
conference - conferenze 2.965
curatela - curatele 0
other - altro 462
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.892
Totale 108.562
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.173 0 0 0 0 0 0 776 290 412 937 575 183
2020/20211.284 72 124 110 87 69 122 110 119 142 111 110 108
2021/20222.592 56 213 142 322 126 187 192 589 69 215 152 329
2022/20232.571 240 115 30 265 421 489 3 238 462 14 248 46
2023/20241.058 66 165 19 108 80 151 43 88 75 9 100 154
2024/20251.396 45 254 86 185 501 322 3 0 0 0 0 0
Totale 19.666